To date, there have been few reports on the effects of teriflunomide on DCs, mainly coming from other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, autoimmune uveitis, etc. Leflunomide, teriflunomide and the derivative (FK778) have been evidenced to inhibit DC maturation and migration, leading to an impaired potency to produce the pro-inflammatory cytokines/chemokines and to initiate proliferation and polarization of CD4+ T cells to TH1/TH17 cells [108–112]. The gene discussed is CD4; the disease is autoimmune disease.